AR029361A1 - GUANIDINE COMPOUNDS ANTAGONIST CYCLES OF THE RECEIVERS OF IL-8, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT - Google Patents

GUANIDINE COMPOUNDS ANTAGONIST CYCLES OF THE RECEIVERS OF IL-8, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Info

Publication number
AR029361A1
AR029361A1 ARP000102556A ARP000102556A AR029361A1 AR 029361 A1 AR029361 A1 AR 029361A1 AR P000102556 A ARP000102556 A AR P000102556A AR P000102556 A ARP000102556 A AR P000102556A AR 029361 A1 AR029361 A1 AR 029361A1
Authority
AR
Argentina
Prior art keywords
manufacture
pharmaceutical composition
receivers
cycles
guanidine compounds
Prior art date
Application number
ARP000102556A
Other languages
Spanish (es)
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AR029361A1 publication Critical patent/AR029361A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01Five-membered rings
    • C07D285/02Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/081,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44Nitrogen atoms not forming part of a nitro radical
    • C07D233/50Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de las fenilureas en el tratamiento de enfermedades mediadas por la quimoquina, interleuquina-8 (IL-8). Compuestos de guanidina cíclica antagonistas de los receptores de la IL-8 que comprende la formula (1) en donde R, R1, R2, Y, m y n tienen los significados dados en la descripcion; además se describen la composicion farmacéutica que los comprende y el uso de los mismos para la manufactura de un medicamento para tratar una enfermedad mediada por una quimoquina donde la quimoquina se une a un receptor alfa o beta de la IL-8 en un mamífero.Use of phenylureas in the treatment of diseases mediated by chemokine, interleukin-8 (IL-8). Cyclic guanidine compounds antagonists of IL-8 receptors comprising formula (1) wherein R, R1, R2, Y, m and n have the meanings given in the description; In addition, the pharmaceutical composition comprising them and the use thereof for the manufacture of a medicament for treating a disease mediated by a chemokine where the chemokine binds to an alpha or beta receptor of IL-8 in a mammal are described.

ARP000102556A 1999-05-28 2000-05-24 GUANIDINE COMPOUNDS ANTAGONIST CYCLES OF THE RECEIVERS OF IL-8, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT AR029361A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13666599P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
AR029361A1 true AR029361A1 (en) 2003-06-25

Family

ID=22473833

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000102556A AR029361A1 (en) 1999-05-28 2000-05-24 GUANIDINE COMPOUNDS ANTAGONIST CYCLES OF THE RECEIVERS OF IL-8, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT

Country Status (20)

Country Link
EP (1) EP1180025A4 (en)
JP (1) JP2003500443A (en)
KR (1) KR20020016806A (en)
CN (1) CN1352554A (en)
AR (1) AR029361A1 (en)
AU (1) AU766999B2 (en)
BR (1) BR0010863A (en)
CA (1) CA2374295A1 (en)
CO (1) CO5170528A1 (en)
CZ (1) CZ20014246A3 (en)
HK (1) HK1045256A1 (en)
HU (1) HUP0201302A3 (en)
IL (1) IL146053A0 (en)
MX (1) MXPA01012267A (en)
NO (1) NO20015774D0 (en)
NZ (1) NZ514728A (en)
PL (1) PL351947A1 (en)
TR (1) TR200103354T2 (en)
WO (1) WO2000072840A1 (en)
ZA (1) ZA200109627B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413302A3 (en) * 1999-07-21 2004-05-12 Kadmus Pharmaceuticals, Inc. Substituted guanidines for the treatment of pain
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
AU6230300A (en) * 1999-07-21 2001-02-13 Kadmus Pharmaceuticals, Inc. Substituted guanidines and the use thereof
WO2002070467A1 (en) 2001-02-26 2002-09-12 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
DE10109204A1 (en) * 2001-02-26 2002-09-19 4Sc Ag Use of new and known diphenylurea compounds for the preparation of a medicament for the inhibition of intracellular protein-degradation pathway
CA2522817A1 (en) 2003-05-01 2004-11-11 F. Hoffmann-La Roche Ag Imidazolin-2-ylaminophenyl amides as ip antagonists
CN101531621B (en) * 2009-04-14 2012-08-15 厦门康奥克科技有限公司 Method for preparing guanidine compound
JP2021501198A (en) * 2017-10-27 2021-01-14 トランスフュージョン ヘルス,リミティド ライアビリティ カンパニー Compositions and Methods for Proliferating Hematopoietic Stem Cells Using Fluorene Derivatives

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605977A (en) * 1898-06-21 Bruno richard seifert
US1953494A (en) * 1926-08-26 1934-04-03 Ig Farbenindustrie Ag Process of preparing substituted guanidines
US3914306A (en) * 1972-09-22 1975-10-21 Rorer Inc William H Guanidines
US5696290A (en) * 1994-09-12 1997-12-09 Monsanto Company Synthesis of penta-substituted guanidines
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp Il-8 receptor antagonists
AR008290A1 (en) * 1996-08-15 1999-12-29 Smithkline Beecham Corp NEW COMPOUNDS CONTAINING GUANIDINE USEFUL AS ANTAGONISTS OF IL-8 RECEPTORS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM PROCEDURE FOR THE PREPARATION OF SUCH COMPOUNDS AND PROCEDURE FOR THE PREPARATION OF INTERMEDIARIES.
WO2000072800A2 (en) * 1999-05-28 2000-12-07 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (en) * 2000-03-24 2001-09-28 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS

Also Published As

Publication number Publication date
TR200103354T2 (en) 2002-06-21
AU5169000A (en) 2000-12-18
WO2000072840A1 (en) 2000-12-07
KR20020016806A (en) 2002-03-06
NO20015774L (en) 2001-11-27
JP2003500443A (en) 2003-01-07
CZ20014246A3 (en) 2002-05-15
NO20015774D0 (en) 2001-11-27
ZA200109627B (en) 2002-11-28
HK1045256A1 (en) 2002-11-22
CA2374295A1 (en) 2000-12-07
HUP0201302A2 (en) 2002-12-28
PL351947A1 (en) 2003-07-14
HUP0201302A3 (en) 2003-02-28
CO5170528A1 (en) 2002-06-27
IL146053A0 (en) 2002-07-25
BR0010863A (en) 2002-02-19
EP1180025A4 (en) 2002-08-28
NZ514728A (en) 2004-04-30
EP1180025A1 (en) 2002-02-20
AU766999B2 (en) 2003-10-30
MXPA01012267A (en) 2002-07-30
CN1352554A (en) 2002-06-05

Similar Documents

Publication Publication Date Title
BR9910144A (en) Chemokine receptor antagonists and their use
AR029198A1 (en) DERIVATIVES OF ADENOSINE 8-MODIFIED HETEROCICLIC N6, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF SUCH DERIVATIVES FOR THE MANUFACTURE OF MEDICINES
BR0016396A (en) New p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
RU2325389C2 (en) Composition and derivatives of substituted azaindoloxoacetapiperazine characterized by antiviral activity
CL2003002756A1 (en) COMPOUNDS DERIVED FROM (1-CARBAMOIL-1,1-DEFENILMETIL) -1- [SUBSTITUTED) RENT] PURROLIDINES; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF THE IRRITABLE INTESTINE SYNDROME OR INCONTINENCE.
DK1194421T3 (en) Selective NPY (Y5) antagonists
UY27939A1 (en) COMPOUNDS
CL2004000788A1 (en) COMPOUNDS DERIVED FROM N- [2-OXO-6- (ARIL OR HETEROARIL) AZEPAN-3-IL] -4- (2-OXO-2,3-DIHIDRO-1H-IMIDAZO [4,5-B] PIRIDIN-1 -IL) PIPERIDINE-1-CARBOXAMIDE, ANTIGONISTS OF CGRP RECEPTORS; PHARMACEUTICAL COMPOSITION; AND USE OF THE COMPOUND IN THE TREATMENT OF D
AR066982A2 (en) HETEROAROMATIC COMPOUNDS REPLACED AS INHIBIDORESS TIROSIN QUINASA, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE PREPARATION OF MEDICINES
CY1109787T1 (en) COMPETITIVE GLUCOGEN RECEPTORS, PREPARATION AND MEDICINAL USES
CY1112376T1 (en) 2,3,4,9-tetrahydro-1H-carvasol derivative as CRTH2 receptor antagonists
BRPI0108395B8 (en) pyrrolopyrimidinone derivatives, preparation and use processes
CY1106514T1 (en) IL-8 RECEPTOR ANTAGONISTS
ES2196063T3 (en) USE OF PROGESTERONE COMPETITIVE ANTAGONIST AGENTS FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE HEMORRAGIES.
AR029361A1 (en) GUANIDINE COMPOUNDS ANTAGONIST CYCLES OF THE RECEIVERS OF IL-8, PHARMACEUTICAL COMPOSITION THAT INCLUDES THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BR0107628A (en) 1,2-diarylbenzimidazoles for treating diseases that are associated with microglial activation
AR029373A1 (en) METHOD FOR THE TREATMENT OF MIGRANES, USING SELECTIVE ANTAGONIST COMPOUNDS OF THE IGLUR5 RECEPTORS, USE OF SUCH SELECTIVE ANTAGONIST COMPOUNDS IN THE MANUFACTURE OF MEDICINES FOR THE TREATMENT OF MIGRANES AND SAVINGS COMPOSED
ES2115616T3 (en) USE OF INOSITOLTRISPHOSPHATE IN THE PREPARATION OF MEDICINES.
AR029637A1 (en) GUANIDINE COMPOUNDS, ANTAGONISTS OF IL-8 RECEPTORS, A PHARMACEUTICAL COMPOSITION CONTAINING THEM AND THE USE OF THEM FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
BR0111267A (en) Bicyclic cyclohexylamines and their use as nmda receptor antagonists
AR024350A1 (en) ANTAGONISTS OF IL-8 RECEIVERS
AR029882A1 (en) DERIVATIVES OF 3A, 4,5,9B-TETRAHIDRO-1H-BENZ [E] INDOL-2-IL AMINA USED IN THE TREATMENT OF OBESITY AND OTHER DISORDERS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND AND THE USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT
EE200100520A (en) N- (2-phenyl-4-aminobutyl) -1-naphthamides as neurokinin-1 receptor antagonists
AR035006A1 (en) DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
BRPI0411729A (en) substituted diketopiperazines and their use as oxytocin antagonists